We are live on ! Find out more
COGT icon

Cogent Biosciences

69 hedge funds and large institutions have $303M invested in Cogent Biosciences in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 27 increasing their positions, 11 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

145% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 11

6% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 17

0% more funds holding

Funds holding: 6969 (0)

17% less funds holding in top 10

Funds holding in top 10: 65 (-1)

18% less capital invested

Capital invested by funds: $370M → $303M (-$67M)

20.46% less ownership

Funds ownership: 113.14%92.68% (-20%)

Holders
69
Holders Change
Holders Change %
0%
% of All Funds
1.21%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.09%
New
18
Increased
27
Reduced
11
Closed
17
Calls
Puts
Net Calls
Net Calls Change

COGT Hedge Fund Activity: Q1 2021 in Review

69 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q1 2021, worth a combined $303M — down 18% from $370M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new COGT positions and 17 closed out — a net gain of 1 holder — while 27 added to existing stakes and 11 trimmed.

The largest buyer was Vanguard Group, adding an estimated $12.3M. The largest seller was Morgan Stanley, cutting an estimated $8.32M.

  • 69 institutional investors held Cogent Biosciences (COGT) as of Q1 2021, unchanged from Q4 2020.
  • Funds reported $303M of Cogent Biosciences stock for Q1 2021, down 18% quarter-over-quarter.
  • 18 funds opened new Cogent Biosciences positions in Q1 2021 and 17 closed out, a net change of +1 holder.
  • The largest Cogent Biosciences buyer in Q1 2021 was Vanguard Group, an estimated $12.3M added.
  • The largest Cogent Biosciences seller in Q1 2021 was Morgan Stanley, an estimated $8.32M sold.

Based on aggregated 13F filings for Q1 2021.